Carcinoembryonic Antigen Market Share

North America Market Forecast

North America carcinoembryonic antigen market is set to capture revenue share of around 39.5% by the end of 2037. The rising prevalence of cancer cases in the region coupled with an advanced healthcare ecosystem drives the sector’s growth. The regional market benefits from the heightened awareness related to CEA testing driving adoption. The U.S. and Canada dominate the revenue share in the North America carcinoembryonic antigen market.

Additionally, rising investments in screening for colorectal cancer are poised to ensure a steady flow of demand for CEA kits in the region. For instance, in February 2024, researchers from the UCLA Health Jonsson Comprehensive Cancer Center were awarded a grant worth USD 3 million to improve follow-up care for colorectal cancer screening, which is poised to drive demand for CEA test kits.

The U.S. holds a dominant share in the North America carcinoembryonic antigen market. The market’s growth in the country is attributed to the rising incidence of colorectal cancer driving demand for CEA kits. For instance, in December 2024, the American Cancer Society (ACS) found that early-onset colorectal cancer (CRC) incidence rates are rising in 27 out of 50 countries globally, and in 14 countries, including the U.S., CRC rates in young adults are increasing. The statistics augur well for the growing demand for CEA test kits to screen CRC cases.

Furthermore, the American Society of Clinical Oncology (ASCO) recommends CEA be performed every three months for the first three years in patients with II or III disease. Such guidelines by premier bodies bode well for the growth of the USA carcinoembryonic antigen sector.

Canada is projected to exhibit robust growth during the forecast period in the North America carcinoembryonic antigen market. The rising cases of colorectal cancer in the country along with robust government-backed plans to improve screening drive demand for CEA kits in the country that manufacturers can leverage. For instance, in March 2022, the Government of Canada announced that colorectal cancer accounted for 12% of all cancers in Canada and around 30 thousand citizens had been diagnosed in 2021.

 Furthermore, the Canadian Colorectal Cancer Coalition has been pushing for campaigns to raise awareness in the country which is poised to drive increased application of CAE tests. For instance, in September 2023, the Canadian Colorectal Cancer Coalition launched a national campaign for communities, organizations, and businesses of all types to sensitize employees on the importance of colorectal cancer screening. Additionally, the publicly funded healthcare system ensures that local health insurance plans cover cancer treatments, which is favorable for the adoption of regular CAE testing.

Europe Market Forecast

The Europe carcinoembryonic antigen market is poised to register rapid growth during the forecast period. A key driver for the market’s growth is owed to the rising cancer estimates of an aging Europe. For instance, in May 2023, the European Cancer Inequalities Registry highlighted that the cancer burden will increase in Europe with incidences higher in men in comparison to women. The statistics indicate that the demand for CEA test kits is poised to increase during the forecast period.

Germany is poised to hold a major revenue share in the Europe carcinoembryonic antigen market. The advanced healthcare infrastructure in the country is poised to benefit the CEA sector of the country. Furthermore, cancer screening programs in the country are poised to drive demand for CEA kits. For instance, in July 2024, the European Lung Foundation stated that lung cancer screening had the potential to diagnose the disease early and improve survival rates. Additionally, the rising prevalence of cancer diagnostics in Europe is poised to impact the market in Germany as well by driving domestic demand for CEA kits.

France is poised to exhibit a favorable growth curve in the carcinoembryonic antigen market of Europe. The rising colorectal cancer rates have driven the demand for screening and CEA test kits to monitor CRC. For instance, the World Cancer Research Fund ranked the metropolitan area of France to account for more than 51 thousand cases in 2022 with CRC more prevalent in men in comparison to women in France. Additionally, advancements in minimally invasive diagnostics are poised to benefit the carcinoembryonic antigen market’s growth.